This is a Phase III, global, multicenter, open-label, randomized study to compare the efficacy and safety of 16 cycles (1 cycle duration=21 days) of atezolizumab (MPDL3280A) treatment compared with be
The dataset comprises a part of the data collected for the CAPiTA trial. Only patients and variables that are included for the current analysis are made publicly. Data from 1325 included patients is s
